Thermo Fisher Raises 2026 Outlook Following Strong Q2 Performance
Thermo Fisher Scientific reported second-quarter revenues of $11.99 billion, representing a year-over-year growth rate of 10%. This performance led the company to raise its full-year revenue and profit outlook for 2026. The firm now expects earnings per share (EPS) in the range of $24.93–$25.33, up from previous guidance of $24.64–$25.12. The company also increased its revenue forecast to between $47.4 billion and $48.1 billion for 2026, reflecting a projected growth rate of 6% to 8%. Thermo Fisher's Q2 results exceeded analyst expectations with an EPS of $6.03 compared to the estimated average of $5.71. The stock rose by nearly 8.7% following the announcement. The strong performance was driven primarily by its laboratory products and biopharma services segment, which accounted for over half of Q2 earnings. Meanwhile, Thermo Fisher's specialty diagnostics business had lower revenue due to a planned divestiture of part of this unit.
Tickers: $TMO